Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
33 Items
Title  Creator  Group name  Publishing year 
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference Laurent et al. EquipeJPP 2025-12
Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting Poty et al. EquipeJPP 2024-10-01
EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose-response and threshold absorbed doses Pouget et al. EquipeJPP 2024-11-12
Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine Hebert et al. EquipeJPP 2024-06-03
The Radiobiology of Radiopharmaceutical Therapy: The Input of Imaging and Radiomics Pouget et al. EquipeJPP 2023
Rapid communication: insights into the role of extracellular vesicles during Auger radioimmunotherapy Karam et al. EquipeJPP 2023
Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors Pouget et al. EquipeJPP 2023-11
Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy Garcia-Prada et al. EquipeCTCS 2023-10-19
Clonogenic assay to measure bystander cytotoxicity of targeted alpha-particle therapy Constanzo et al. EquipeJPP 2023
An EANM position paper on advancing radiobiology for shaping the future of nuclear medicine EANM Radiobiology Working Group: et al. EquipeJPP 2023-01
Therapeutic antibodies - natural and pathological barriers and strategies to overcome them Al Ojaimi et al. EquipeJPP 05/2022
Status of radiobiology in molecular radionuclide therapy - Hope for the future Nonnekens et al. EquipeJPP 2022
Immunostimulatory effects of radioimmunotherapy Constanzo et al. EquipeJPP 2022-02
From the target cell theory to a more integrated view of radiobiology in Targeted radionuclide therapy: The Montpellier group's experience Pouget et al. EquipeJPP 2022
Basics of radiobiology Pouget EquipeJPP 2022
A Recanalized Umbilical Vein Hypermetabolic Thrombosis Mimicked an Hepatocellular Carcinoma Recurrence: A New Pitfall? Fidani et al. EquipeJPP 2022-07-01
Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide Idrissou et al. EquipeJPP 2021-06-29
Revisiting the Radiobiology of Targeted Alpha Therapy Pouget and Constanzo EquipeJPP 2021
Radiation-Induced Immunity and Toxicities: The Versatility of the cGAS-STING Pathway Constanzo et al. EquipeJPP 2021
In Silico Investigation of the Biological Implications of Complex DNA Damage with Emphasis in Cancer Radiotherapy through a Systems Biology Approach Pavlopoulou et al. EquipeJPP 2021-12-15
First Symposium of the European Working Group on the Radiobiology of Molecular Radiotherapy Cornelissen et al. EquipeJPP 2021-07-01
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest Pichard et al. EquipeNB May 2020
Synthesis and in vitro antitumour activity of carboplatin analogues containing functional handles compatible for conjugation to drug delivery systems Re?nik et al. EquipeCG 2020-11-15
Comparison of commercial dosimetric software platforms in patients treated with 177 Lu-DOTATATE for peptide receptor radionuclide therapy Mora-Ramirez et al. EquipeJPP 2020-09
Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept Rondon et al. EquipeJPP 2019
12>>>
33 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés